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Abstract 
We report a case of HIV-1 superinfection (HSI) with a clade B, triple class-resistant virus in a 
patient successfully controlling viremia with continuous cART started 8 years earlier during 
primary HIV infection. The course of HIV infection prior to HSI was monitored in both the 
source partner and recipient (8 and 11 years, respectively) and 4 years following HSI. This 
case report demonstrates re-infection with HIV-1 despite effective cART. 
Background 
HIV-1 superinfection (HSI), that is, infection with a second strain after the first has been 
established, has been reported since 2002 mainly involving HIV group M clades
 
{1-6} and in 
a smaller proportion as inter-group recombinant forms {7-8}. Overall, HSI has been most 
often observed in untreated patients, during treatment interruption, and in seroconcordant 
couples with poor viral suppression {9}. Here we report the onset and 4 year follow-up of 
HSI with a triple class resistant clade B virus in a man on effective combined antiretroviral 
treatment (cART). 
HIV superinfection  
Briefly, blood samples were obtained from 2 men (M1 and M2) chronically infected with 
HIV-1 and sexual partners since 2006. M2 was diagnosed with HIV infection in 1994 at stage 
A2 with full Western blot seroconversion, and developed triple class antiretroviral drug 
resistance as a consequence of weak adherence to ART, leading to virologic failure. M2 
experienced uncontrolled viremia (range: 3 to 4 logs of viral RNA) until September 2008 
when a salvage treatment regimen reduced his viral load to undetectable for the first time 
(Figure 1a).  M1 was diagnosed in 2000 with primary HIV infection, initiated cART in 2000, 
and remained on cART with undetectable viremia and no drug resistance mutations through 
the end of 2007 (Figure 1b).  cART first regimen consisted of ZDV+3TC+EFV. In 2001 EFV 
was replaced by LPV/r due to EFV neurologic intolerance. Therapy was simplified in 2002 
3 
with the association of ZDV/3TC/ABC (Trizivir

). M1 was also a vaccine recipient in the 
therapeutic HIV vaccine trial TheraVac01 {10}.
 
Briefly, the trial was an open-label one arm 
study that took place in Lausanne, Switzerland. All subjects (n=10) were immunized with 
NYVAC-B (Gag/Pol/Nef polygene of HIV IIIB, and Env clade B of HIV BX08) 
intramuscularly (10E7.4 CCID50/mL) at weeks W0 and W4. M1 was assigned the code 
TH#04 and was immunized on May 17 (W0) and on June 14 (W4) 2006, respectively. 
In February 2008, M1 presented with a plasma viral load of 280 copies/mL that increased 
over the following year. Genotypic analysis from 2008 onward revealed 25 new drug 
resistance mutations to NRTI (6), NNRTI (5) and PI (14). Of note, this resistance profile 
shared 22 of 23 mutations (96%) found contemporaneously in M2. The shared mutations 
included  NRTI resistance mutations 41L, 74I, 184V, 215Y, NNRTI mutations, 98G, 103N, 
108I and PI mutations 10V, 13V, 20R, 32I, 33I, 46I, 47V, 50V, 71I, 77I. M1 also developed 
75T (NRTI), 115/Y (NNRTI) and 82A (PI) polymorphisms. 
Molecular and Phylogenetic analyses  
We obtained viral gene sequences from M1 from July 2000 (N=11 ~9kb near full-length 
genomes, NFLG), February 2008 (N=12 gag and env genes) and May of 2008 (N=14 gag and 
N=16 env genes), and from M2 in January (N=10 NFLG) and March of 2008 (N=7 NFLG). 
All 86 viral sequences were assigned to clade B. Additionally, all sequences from M1 
obtained from 2008 clustered with M2 sequences from the same year and were 
phylogentically unrelated to M1 sequences from 2000 (data not shown). This indicated HSI of 
M1 with substantial or complete replacement with virus from M2. No recombination between 
the M1 and M2 strains was observed. 
Four years follow-up 
M1’s viral load increased from undetectable to >3 logs after HSI, decreasing progressively 
from 2009 to 2012 without cART modification. A continuous drop of CD4+ cells of at least 
4 
10% was observed from time of HSI detection in February 2008 (30.8%) through April 2011 
(18%). However, in April 2012, M1’s CD4+ count recovered to 25.4% (757 cell/mm3) 
(Figure 1b). Patient M2’s follow-up was taken over by a general practitioner in 2009 after 3 
consecutive undetectable viral loads following start of salvage antiretroviral treatment (Figure 
1a).  
 
Discussion and conclusions 
We detected superinfection and replacement by HIV-1 clade B triple class-resistant virus in a 
patient on long-term cART controlled infection, with the initial indicator of HSI being a 
detectable and increasing viral load.   
Other resistance mutations not found in the superinfecting strain also emerged following HSI, 
though their origin is unclear. They could have been present as minority populations prior to 
superinfection or transmitted with the superinfecting strain but below the detection level of 
our assessment of M2’s quasispecies (no additional specimen was available for massively 
parallel sequencing). Despite HSI with a triple class resistant virus, M1’s antiretroviral 
treatment remained unchanged. During 4 years of additional follow-up, a continuous drop of 
viral load occurred, followed by CD4+ recovery in the last year (Figure 1b). The impact of 
HSI in CD4+ decline and disease progression following subtype B coinfection was initially 
suggested by Gottlieb and colleagues {11}. Evidence of CD4+ T-cell decline as the initial 
indicator of HSI was also reported in untreated patients during primary HIV infection as well 
as in untreated elite controllers {12-14}. 
In contrast to previous reports of superinfecton among long-term known seroconcordant 
couples undergoing ART
 
{9}, this report underscores the fragile chemoprophylactic barrier 
exerted by ART despite excellent adherence. Apart from the complex resistance profile of the 
superinfecting strain present in patient M2, we cannot rule out the role of viral escape to 
5 
preexisting CTL or antibody responses in the establishment of the second infection, which 
involves the same clade and therefore, to some extent challenged similar immune signatures 
in the superinfected individual, as reported elsewhere {15-16}. Of interest, M1’s HIV-specific 
T-cell responses were enriched following NYVAC-B immunizations (weeks 0 and 4) and 21 
months prior to superinfection {10}. Briefly, two novel Env/Pol vaccine-induced responses 
emerged at W2 and remained present throughout the study with a clear decline by W48 {10}, 
greater than 1 year prior to HSI. The protective role of these vaccine-induced responses to 
prevent a second infection with a resistant virus, as well as their longevity, remains unproven.  
Haplotypes such as HLA-B3503 have been shown to be associated with HIV-1 superinfection 
susceptibility as a consequence of late or weak immune response priming {15}. In this regard, 
patient M1 carries HLA haplotype A*30/23, B*35/44, DRB1*14/04 (performed by PCR-SSO 
using LabType
®
 kit on the Luminex System). He also had no CCR5-delta 32 mutations (in-
house PCR modified from Wilkinson DA et al., 1998) {17}.  
In summary, patient M1’s superinfection onset agrees with current knowledge on host factors 
and re-exposure to a resistant strain, and demonstrates the previously unexpected scenario of 
re-infection during well-established chronic infection, despite continuously suppressed 
viremia with cART started during primary HIV infection. 
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